# Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide

> **NCT04361058** · PHASE1 · WITHDRAWN · sponsor: **SCRI Development Innovations, LLC**

## Conditions studied

- Leukemia, Myeloid, Acute
- Myelodysplastic Syndromes
- Myelodysplastic Syndrome Acute Myeloid Leukemia

## Interventions

- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT04361058
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-04-13
- **Primary completion:** 2021-04-20
- **Final completion:** 2021-04-20
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The single site that was deemed appropriate for this study was unable to enroll patients. Closed due to slow accrual.
- **Last updated:** 2023-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04361058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04361058, "Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04361058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*